Replies to post #37830 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

OK, I see your point. But the territories don't overlap. As I recall it (which could be off...), the 'two indication' question was--Could CX-1739 be licensed to one company for RD, and a different one for ADHD--in North America...

Would acceptance of the geographical split be affected if the indications differed? Offhand, I can't think of an example where that's occurred, and I suppose one could argue that a US partner might worry about elderly Korean patients receiving the same drug for AD or PD. But the principle of splitting off Asia is so embedded that I don't think this would be a significant issue. I look forward to the day that a US partnering prospect is so interested in an Ampakine that they'd give any thought to the question.

NeuroInvestment

[ombowstring]

gfp, I don't know why you're hinting that there might be a problem with CX1739 or CX1846. Conversely, if Samyang ran clinical trials and the data showed efficacy, that would be a plus for Cortex in negotiations with other potential partners (although the results of a trial run by Samyang would be probably at least a year away and thus this might be a moot point). we don't want to shy away from clinical trials; we want them to take place. AMPAKINES are showing reasonably good results in all trials so far so the more trials that are run, the better Cortex should look. I just don't see what you're suggesting as a big problem. And it may never eventuate.

Cortex has to come up with something bigger than this development anyway, and soon.